In vitro immunomodulatory activity of ruthenium complexes

Inflammation Research

Volumn 52, Issue 6, 2003, Pages 263-271

  Newcomb, J R ^a,f   Rivnay, B ^b,f   Bastos, C M ^f   Ocain, T D ^c,f   Gordon, K ^f   Gregory, P ^f   Turci, S M ^a,f   Sterne, K A ^f   Jesson, M ^d,f   Krieger, J ^e,f   Jenson, J C ^f   Jones, B ^d,f  

^a AMGEN INC   (United States)

^b Repromedix Corporation   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

^d Point Therapeutics   (United States)

^e AutoImmune Inc   (United States)

^f Procept Inc   (United States)

Author keywords

Cellular Activation; Immunomodulators; T lymphocytes

Indexed keywords

CYCLOSPORIN A; IMMUNOMODULATING AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MYCOPHENOLIC ACID; RAPAMYCIN; RUTHENIUM COMPLEX; RUTHENIUM RED; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ARTICLE; CELL CYCLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DNA SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; T LYMPHOCYTE ACTIVATION;

EID: 10744229221     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-003-1169-5     Document Type: Article

References (36)

1. Sigal NH and Dumont FJ. Cyclosporin A, FK-506, and Rapamycin: Pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992; 10: 519-60.
2. Lin CS, Boltz RC, Siekierka JN, Sigal NH. FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. Cellular Immunology 1991; 133: 269-84.
3. Bierer BE, Hollander G, Fruman D, Burakoff SJ. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Current Opinion in Immunol. 1993; 5: 763-73.
4. Sehgal SN, Molnar-Kimber K, Ocain TD, Weichman BM. Rapamycin: A Novel Immunosuppressive Macrolide. Med Res Reviews 1994; 14: 1-22.
5. Morris RE, Wu J, Shorthouse R. A Study of the Contrasting Effects of Cyclosporine, FK 506, and Rapamycin on the suppression of Allograft Rejection. Transplant Proc, 1990; 22: 1638-41.
6. Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990; 22: 1659-62.
7. Van Duyne GD, Standaert RF, Karplus PA, Schreiber SL, Clardy J. Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. Science 1991; 252: 839-42.
8. Griffith JP, Kim JL, Kim EE, Sintchak MD, Thomson JA, Fitzgibbon MJ et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 1995; 82: 507-22.
9. Kissinger, CR, Parge, HE, Knighton, DR, Lewis, CT, Pelletier LA, Tempczyk et al. Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature 1995; 378: 641-4.
10. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and Rapamycin. Journal Immunol 1990; 144: 251-8.
11. Liu J, Farmer JDF, Lane WS, Friedman J, Weissmann I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-15.
12. Sigal NH., Siekierka JJ. Inhibition of human T cell activation by FK506, Rapamycin, and cyclosporine A. Transplant Proc 1991; 23: 1-5.
13. McCaffrey PG, Perrino BA, Soderling TR, Rao A. NF-ATp, a T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. J Biol Chem 1993; 268: 3747-52.
14. 1 progression. Cell 1993; 73: 585-96.
15. Brown EJ, Albers MW, Shin TB, Ichikawa K, C.T. Keith CT, Lane WS et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369: 756-8.
16. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT-1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78: 35-43.
17. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996; 273: 239-42.
18. s6k by inducing dephosphorylation of the same subset of sites. J Biol Chem 1995; 270: 21396-403.
19. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee M-H et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372: 570-3.
20. Kopf-Maier P. Complexes of metals other than platinum as antitumour agents. Eur J Clin Pharmacol 1994; 47: 1-16.
21. ++ Transport. FEBS Letters 1974; 46: 109-19.
22. 2+ release channel (Ryanodine receptor) by calmodulin. Biochem Biophys Res Commun. 1995; 213: 1082-90.
23. Sasaki T., Naka, Nakamura MF, Tanaka T. Ruthenium red inhibits the binding of calcium to calmodulin required for enzyme activation. J Biol Chem 1992; 267: 21518-23.
24. 2+ binding proteins. Anal Biochem 1990; 188: 123-31.
25. Garcia-Hirschfeld J, Lopez-Briones LG, Belmonte C, Valdeolmillos M. Intracellular free calcium responses to protons and capsaicin in cultured trigeminal neurons. Neuroscience 1995; 67: 235-43.
26. Ortiz GG, de la Mora-Rivas G, Cardenas-Ortega A, Orbach-Arbuys S, Bravo-Cuellar A, Feria-Velasco A. Hepatotoxicity induced by a single ip injection of ruthenium red. Biomed Pharmacother 1992; 46: 115-9.
27. Ocain T., Bastos CM, Gordon KA, Granstein RD, Jenson JC, Jones B et al. A novel series of low molecular weight immunosuppressive agents. Transplant. Proc 1996; 28: 3032-4.
28. Dwyer DS, Gordon K, Jones B. Ruthenium red potently inhibits immune responses both in vitro and in vivo. Int J Immunopharmacol 1995; 17: 931-40.
29. Bastos CM, Gordon KA, Ocain TD. Synthesis and immunosuppressive activity of ruthenium complexes. Bioorganic and Medicinal Chemistry Letters 1998; 8: 147-50.
30. Ford PC, Rudd D., Gaunder R, Taube H. Synthesis and properties of pentaaminepyridineruthenium (II) and related pentaamineruthenium complexes of aromatic nitrogen heterocycles. J Am Chem. Soc. 1968; 90: 1187.
31. Sundberg RJ, Bryan RF, Taylor IF Jr, Taube H. Nitrogen-bound and carbon-bound imidazole complexes of ruthenium ammines. J Am Chem Soc 1974; 96: 381.
32. Hori T, Uchiyama T, Tsudo M, Umadome H, Ohno H, Fukuhara S et al. Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood 1987; 70: 1069-72.
33. Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol 1993; 14: 353-80.
34. Webb SR, Gascoigne NRJ. T-cell activation by superantigens. Curr Opin Immunol 1994; 6: 467-75.
35. Allesio E, Attia WM, Calligaris M, Cauci S, Dolzani L, Mestroni G et al. In: Micolini, M., editor. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Boston, MA: Martinus Nijhoff Press 1988:6-17.
36. June C, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunology Today 1994; 15: 321-31.